ACST Acasti Pharma, Inc.

+0.03  (2%)
Previous Close 1.23
Open 1.23
Price To book 0.91
Market Cap 13.50M
Shares 10,712,000
Volume 15,088
Short Ratio 1.97
Av. Daily Volume 64,273

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
CaPre (TRIFECTA trial)

Latest News

  1. Acasti Pharma Presents CaPre Clinical Data at National Lipid Association Scientific Sessions
  2. Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities
  3. Acasti Pharma to Present CaPre Omega-3 Bridging Study Results at National Lipid Association Scientific Sessions
  4. Acasti Pharma Provides Update On CaPre Phase 3 Development Program
  5. Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading Cardiovascular Disease Experts
  6. Acasti Pharma Grants Incentive Stock and Options
  7. Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed Offering of Units
  8. Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma
  9. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q3, 2017 By the Numbers : January 16, 2017
  10. Acasti reports 3Q loss
  11. Acasti Pharma Reports Third Quarter 2017 Financial Results
  12. Acasti Pharma Appoints Linda O'Keefe as Chief Financial Officer
  13. Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV
  14. Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre
  15. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q2, 2017 By the Numbers : October 14, 2016
  16. Acasti Pharma Reports Second Quarter 2017 Financial Results
  17. McDonald’s Corporation (MCD), AcelRx Pharmaceuticals Inc. (ACRX) & More: Here’s Why These Stocks Are Trending Today
  18. Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
  19. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q1, 2017 By the Numbers : July 22, 2016